Wedbush Comments on argenx’s Q4 Earnings (NASDAQ:ARGX)

argenx SE (NASDAQ:ARGX) – Equities researchers at Wedbush boosted their Q4 2024 earnings estimates for argenx in a report released on Monday, January 13th. Wedbush analyst D. Nierengarten now expects that the company will earn $2.74 per share for the quarter, up from their prior forecast of $1.09. Wedbush currently has a “Outperform” rating and a $655.00 target price on the stock. The consensus estimate for argenx’s current full-year earnings is $2.17 per share. Wedbush also issued estimates for argenx’s Q1 2025 earnings at $3.11 EPS, Q2 2025 earnings at $4.15 EPS, Q3 2025 earnings at $5.12 EPS, Q4 2025 earnings at $5.95 EPS, FY2025 earnings at $18.37 EPS, FY2026 earnings at $33.33 EPS and FY2027 earnings at $43.65 EPS.

argenx (NASDAQ:ARGX) last announced its quarterly earnings data on Thursday, October 31st. The company reported $1.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $1.29. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The company had revenue of $588.88 million during the quarter, compared to analysts’ expectations of $543.29 million. During the same quarter in the prior year, the company earned ($1.25) EPS.

Several other brokerages have also recently issued reports on ARGX. Raymond James restated a “strong-buy” rating and issued a $605.00 target price on shares of argenx in a report on Thursday, October 10th. Robert W. Baird lowered shares of argenx from an “outperform” rating to a “neutral” rating and upped their price objective for the company from $515.00 to $650.00 in a report on Friday, November 1st. HC Wainwright reaffirmed a “buy” rating and set a $717.00 target price (up from $670.00) on shares of argenx in a research note on Tuesday. Guggenheim increased their price target on shares of argenx from $585.00 to $665.00 and gave the company a “buy” rating in a research note on Friday, November 1st. Finally, Oppenheimer restated an “outperform” rating and set a $675.00 price target (up previously from $646.00) on shares of argenx in a report on Thursday, November 21st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, argenx currently has an average rating of “Moderate Buy” and an average target price of $658.39.

argenx Price Performance

ARGX stock opened at $640.52 on Thursday. argenx has a 1 year low of $349.86 and a 1 year high of $678.21. The firm has a market capitalization of $38.67 billion, a PE ratio of -727.86 and a beta of 0.59. The business has a 50 day simple moving average of $620.19 and a 200-day simple moving average of $555.67.

Institutional Investors Weigh In On argenx

Large investors have recently added to or reduced their stakes in the business. Cromwell Holdings LLC boosted its position in argenx by 73.3% in the 3rd quarter. Cromwell Holdings LLC now owns 156 shares of the company’s stock valued at $85,000 after buying an additional 66 shares during the period. GAMMA Investing LLC raised its stake in shares of argenx by 47.5% in the third quarter. GAMMA Investing LLC now owns 174 shares of the company’s stock valued at $94,000 after acquiring an additional 56 shares in the last quarter. Point72 Hong Kong Ltd purchased a new position in argenx in the second quarter valued at $76,000. SG Americas Securities LLC grew its stake in argenx by 6.2% during the 4th quarter. SG Americas Securities LLC now owns 358 shares of the company’s stock worth $220,000 after purchasing an additional 21 shares in the last quarter. Finally, Fulton Bank N.A. purchased a new stake in argenx during the 4th quarter worth about $226,000. 60.32% of the stock is owned by hedge funds and other institutional investors.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.